JP2024510503A5 - - Google Patents

Info

Publication number
JP2024510503A5
JP2024510503A5 JP2023557352A JP2023557352A JP2024510503A5 JP 2024510503 A5 JP2024510503 A5 JP 2024510503A5 JP 2023557352 A JP2023557352 A JP 2023557352A JP 2023557352 A JP2023557352 A JP 2023557352A JP 2024510503 A5 JP2024510503 A5 JP 2024510503A5
Authority
JP
Japan
Application number
JP2023557352A
Other languages
Japanese (ja)
Other versions
JPWO2022197756A5 (https=
JP2024510503A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2022/020479 external-priority patent/WO2022197756A1/en
Publication of JP2024510503A publication Critical patent/JP2024510503A/ja
Publication of JP2024510503A5 publication Critical patent/JP2024510503A5/ja
Publication of JPWO2022197756A5 publication Critical patent/JPWO2022197756A5/ja
Pending legal-status Critical Current

Links

JP2023557352A 2021-03-17 2022-03-16 血漿カリクレイン阻害剤 Pending JP2024510503A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202163162477P 2021-03-17 2021-03-17
US63/162,477 2021-03-17
PCT/US2022/020479 WO2022197756A1 (en) 2021-03-17 2022-03-16 Plasma kallikrein inhibitors

Publications (3)

Publication Number Publication Date
JP2024510503A JP2024510503A (ja) 2024-03-07
JP2024510503A5 true JP2024510503A5 (https=) 2025-03-24
JPWO2022197756A5 JPWO2022197756A5 (https=) 2025-03-24

Family

ID=81327137

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2023557352A Pending JP2024510503A (ja) 2021-03-17 2022-03-16 血漿カリクレイン阻害剤

Country Status (5)

Country Link
US (1) US20240382482A1 (https=)
EP (1) EP4308228A1 (https=)
JP (1) JP2024510503A (https=)
CN (1) CN117396474A (https=)
WO (1) WO2022197756A1 (https=)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20200143376A (ko) 2018-03-13 2020-12-23 샤이어 휴먼 지네틱 테라피즈 인크. 혈장 칼리크레인 억제제로서의 치환된 이미다조피리딘 및 이의 용도
CN114667289B (zh) 2019-09-18 2025-08-26 武田药品工业有限公司 杂芳基血浆激肽释放酶抑制剂
EP4031547B1 (en) 2019-09-18 2024-07-17 Takeda Pharmaceutical Company Limited Plasma kallikrein inhibitors and uses thereof
CN117396473A (zh) * 2021-03-17 2024-01-12 武田药品工业株式会社 血浆激肽释放酶的咪唑并吡啶基抑制剂

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4911920A (en) 1986-07-30 1990-03-27 Alcon Laboratories, Inc. Sustained release, comfort formulation for glaucoma therapy
FR2588189B1 (fr) 1985-10-03 1988-12-02 Merck Sharp & Dohme Composition pharmaceutique de type a transition de phase liquide-gel
ATE141502T1 (de) 1991-01-15 1996-09-15 Alcon Lab Inc Verwendung von karrageenan in topischen ophthalmologischen zusammensetzungen
US5212162A (en) 1991-03-27 1993-05-18 Alcon Laboratories, Inc. Use of combinations gelling polysaccharides and finely divided drug carrier substrates in topical ophthalmic compositions
US6309853B1 (en) 1994-08-17 2001-10-30 The Rockfeller University Modulators of body weight, corresponding nucleic acids and proteins, and diagnostic and therapeutic uses thereof
US6887870B1 (en) * 1999-10-12 2005-05-03 Bristol-Myers Squibb Company Heterocyclic sodium/proton exchange inhibitors and method
AU2008309517B2 (en) * 2007-10-12 2013-03-14 Astrazeneca Ab Inhibitors of protein kinases
EP2627178B1 (en) * 2010-10-11 2018-05-02 Merck Sharp & Dohme Corp. Quinazolinone-type compounds as crth2 antagonists
EP3087067B1 (en) * 2013-12-26 2018-10-24 Takeda Pharmaceutical Company Limited 4-(piperrazin-1-yl)-pyrrolidin-2-one compounds as monoacylglycerol lipase (magl) inhibitors
CN106794181A (zh) * 2014-06-04 2017-05-31 托马斯·黑勒戴药物研究基金会 用于治疗炎性和自身免疫性病况的mth1抑制剂
WO2016010108A1 (ja) * 2014-07-18 2016-01-21 塩野義製薬株式会社 含窒素複素環誘導体およびそれらを含有する医薬組成物
WO2016201052A1 (en) 2015-06-12 2016-12-15 Global Blood Therapeutics, Inc. Bridged bicyclic kallikrein inhibitors
IL263235B (en) 2016-05-31 2022-07-01 Kalvista Pharmaceuticals Ltd History of pyrazoles as plasma kallikrein inhibitors
KR20200143376A (ko) * 2018-03-13 2020-12-23 샤이어 휴먼 지네틱 테라피즈 인크. 혈장 칼리크레인 억제제로서의 치환된 이미다조피리딘 및 이의 용도

Similar Documents

Publication Publication Date Title
JP2024510503A5 (https=)
BR102022025291A2 (https=)
CL2025004149A1 (es) Método y sistema para la recuperación de elementos valiosos a partir de la materia prima derivada de los relaves de minas de cobre.
BR102023014872A2 (https=)
BR102023012440A2 (https=)
BR102023010976A2 (https=)
BR102023009641A2 (https=)
BR102023008688A2 (https=)
BR102023007252A2 (https=)
BR102023005164A2 (https=)
BR102023001877A2 (https=)
BR102023000289A2 (https=)
BR102022026909A2 (https=)
BR202022009269U2 (https=)
BR202022005961U2 (https=)
BR202022001779U2 (https=)
BR202022000931U2 (https=)
CN307049990S (https=)
CN307046488S (https=)
BY13157U (https=)
BY13176U (https=)
BY13175U (https=)
BY13174U (https=)
BY13172U (https=)
CN307044824S (https=)